Trimethoprim
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Using the txgnn-pipeline skill to confirm Netherlands deployment context. Now generating the report following the Drug Repurposing Evaluation Report Prompt (v5).
Trimethoprim: From Bacterial Infections to Punctate Epithelial Keratoconjunctivitis
One-Sentence Summary
Trimethoprim is a dihydrofolate reductase (DHFR) inhibitor classically used to treat bacterial infections, including urinary tract and respiratory infections. The TxGNN model predicts it may be effective for Punctate Epithelial Keratoconjunctivitis (PEK), with a prediction score of 99.57%. However, no clinical trials and no published literature currently support this specific application — the prediction rests entirely on model inference.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available per NL records (generally: bacterial infections incl. UTI) |
| Predicted New Indication | Punctate Epithelial Keratoconjunctivitis |
| TxGNN Prediction Score | 99.57% |
| Evidence Level | L5 |
| NL Market Status | Not registered |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, Trimethoprim is a selective inhibitor of bacterial dihydrofolate reductase (DHFR), blocking the folate synthesis pathway essential for bacterial DNA replication. It is active against gram-positive organisms (particularly Staphylococcus aureus and Streptococcus pneumoniae) and selected gram-negative species such as Haemophilus influenzae — all of which are common causative agents of ocular surface infections. When combined with Polymyxin B (as in the marketed ophthalmic product Polytrim, approved in the USA), the formulation covers the principal pathogens of bacterial conjunctivitis.
Punctate epithelial keratoconjunctivitis (PEK) is a distinct clinical entity, predominantly of viral (adenoviral) aetiology, presenting as diffuse punctate lesions on the corneal epithelium and conjunctiva. The high TxGNN score (99.57%, rank 933) most plausibly reflects disease-graph proximity between PEK and bacterial conjunctivitis rather than a direct pharmacological link: within the knowledge graph, both conditions share the ocular surface as a disease locus, and bacterial conjunctivitis has well-documented clinical evidence for trimethoprim-containing ophthalmic preparations.
Critically, however, there is no established mechanism by which Trimethoprim would address the primary adenoviral driver of PEK, nor any preclinical data suggesting anti-inflammatory or antiviral activity relevant to this condition. The prediction should be treated as hypothesis-generating until mechanistic or empirical evidence emerges.
Clinical Trial Evidence
Currently no related clinical trials registered for punctate epithelial keratoconjunctivitis.
Literature Evidence
Currently no related literature available for punctate epithelial keratoconjunctivitis.
Netherlands Market Information
No marketing authorizations (RVG numbers) for Trimethoprim are recorded in this dataset for the Netherlands.
Note for reviewers: Trimethoprim and co-trimoxazole (trimethoprim/sulfamethoxazole) formulations are in clinical use across Europe, including ophthalmic preparations (e.g., Polytrim eye drops). The absence of records here likely reflects a data gap in the current Evidence Pack rather than an actual absence of Dutch registrations. CBG-MEB records should be consulted directly to confirm current authorization status before drawing regulatory conclusions.
Safety Considerations
Please refer to the SmPC (Summary of Product Characteristics / Samenvatting van de Productkenmerken) for complete safety information, including warnings, contraindications, and drug interactions. No safety data is available in the current Evidence Pack.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a very high TxGNN prediction score, the evidence base for Trimethoprim in punctate epithelial keratoconjunctivitis is entirely absent (Evidence Level L5 — model prediction only). PEK’s predominantly viral aetiology does not align with Trimethoprim’s antibacterial mechanism of action, and the high score is best interpreted as an artifact of disease-graph proximity to bacterial conjunctivitis rather than a clinically actionable signal.
To proceed, the following is needed:
- Mechanistic validation: Clarify whether Trimethoprim (or host DHFR inhibition) has any relevance to adenoviral PEK pathophysiology, or whether the prediction could instead support use in PEK with confirmed bacterial superinfection
- Preclinical data: In vitro or animal model studies specifically addressing trimethoprim activity in PEK
- Disease stratification: Assess whether a subgroup of PEK with documented bacterial secondary infection might represent a more tractable indication for trimethoprim-based ophthalmic therapy
- NL regulatory verification: Confirm current CBG-MEB authorization status for Trimethoprim and related ophthalmic formulations via direct registry query
- SmPC review: Obtain the full SmPC to complete the safety profile, particularly regarding ophthalmic use and known contraindications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.